At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 619 enrolled
Drug / intervention
TD-4208 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 3 clinical trial evaluating TD-4208 and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 619 participants across 1 site.
Detailed Summary
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsTheravance Biopharma
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartSep 2015
Primary CompletionAug 2016
Study CompletionSep 2016
TodayJul 2026
First PostedJun 1, 2015
Enrollment StartSep 1, 2015
Primary CompletionAug 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.1 years ago
Interventions
TD-4208drug
Placebodrug